News
The discovery of an operable lesion in the brain makes it possible to control epileptic seizures triggered by eating act with surgery
A study led by the Bellvitge Biomedical Research Institute (IDIBELL) and the Bellvitge University Hospital (HUB) has discovered an encephalocele in the right temporal pole of the brain in some of patients.
M Carolina Florian new ICREA Research Professor
Dra. M Carolina Florian, group leader at IDIBELL, has been appointed as an ICREA Research Professor. ICREA, the Catalan Institution for Research and Advanced Studies, offers permanent, tenured positions to the most talented and extraordinary scientists and academics to come and work in Catalonia. Over the years these positions have become a synonym for global academic excellence.
Two IDIBELL teams are granted two research projects on personalized medicine
Two researchers from IDIBELL will lead two multicenter research projects on precision personalized medicine: The PRECISION-ILD project lead by Dr Maria Molina (IDIBELL and Bellvitge University Hospital) and IMPaCT_VUSCan project, led by Dr Conxi Lázaro (IDIBELL and Catalan Oncology Institute). Both projects will last for three years, are financed by the Next Generation EU funds and have bee assigned by the Health Institute Carlos III (ISCIII) in a specific call on personalized medicine.
The 6th IDIBELL sLHam of women scientists will claim the role of women and girls in science
The event will be in the Barradas Auditorium in L’Hospitalet de Llobregat on Friday, February 10, at 7 p.m. The 6th sLHam incorporates a novelty: Together with six woman scientists from IDIBELL, two junior sLHamers from the Bellvitge Institute will participate.
New treatment options are opening up in the field of cutaneous lymphomas thanks to an immunotherapy-based drug
According to the results, brentuximab vedotin is effective and safe for some rare types of cutaneous T-cell lymphomas (LCCT)
A group of excellence composed of IDIBELL researchers and Cardiology professionals from the HUB joins the CIBER of Cardiovascular Diseases
The group linked to IDIBELL investigates personalized precision strategies for the interdisciplinary approach to heart failure in its evolutionary phases. Their research will contribute to the objective of the CIBERCV: reduce the impact of cardiovascular diseases and develop actions of excellence in translational cardiovascular research and training.
Dr. Josep Comín, co-author of two publications in Nature Medicine and JACC on a new drug against heart failure
The international group of scientists who have discovered the benefits of dapagliflozin in the treatment of heart failure, including Dr. Josep Comín, head of the IDIBELL BIO-Heart Research Group on Cardiovascular Diseases and the Cardiology Service of the Hospital de Bellvitge, has published new disaggregated results of this research in the leading scientific journals Nature Medicine and the Journal of the American College of Cardiology (JACC).
Two brain regions size could predict the psychological behavioral therapy effectiveness in children with OCD
A study by the Bellvitge Biomedical Research Institute (IDIBELL), the Bellvitge University Hospital, the University of Barcelona, and CIBERSAM observes that children with increased volume of two prefrontal cortex structures respond better to cognitive behavioral therapy.
Presentation of the new confocal microscope of the Bioimaging platform
The Bioimaging Platform of the IDIBELL Scientific-technical Services has incorporated a new high-performance equipment, which is the Carl Zeiss LSM980 confocal microscope equipped with the Airyscan2 detector